RECCE PHARMACEUTICALS LTD — Director's Dealing 2020

Sep 1, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Recce Pharmaceuticals Ltd (Company) ABN 73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Hamilton Bray Graham
Date of last notice	13 July 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving riseto the relevant interest.	N/A
Date of change	28 August 2020
No. of securities held prior tochange	Total ordinary shares prior to change: 5,238,120Direct Interest:1. 2,450,620 ordinary shares2. 389,712 Class B Performance Shares3. 389,712 Class D Performance SharesIndirect Interest:Mr. James Graham <J Graham Family A/c>1. 2,137,500 ordinary shares2. 356,250 Class B Performance Shares3. 356,250 Class D Performance SharesBulleen Pty Ltd1. 650,000 ordinary shares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	Fully Paid Ordinary Shares and Class DPerformance Shares	Fully Paid Ordinary Shares and Class DPerformance Shares
Number acquired	745,962 fully paid ordinary shares (uponconversion of 745,962 Class D PerformanceShares)
Number disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details andestimated valuation	Nil
No. of securities held after change	Total ordinary shares held after change: 5,984,082Direct Interest:1. 2,840,332 ordinary shares2. 389,712 Class B Performance SharesIndirect Interest:Mr. James Graham <J Graham Family A/c>1. 2,493,750 ordinary shares2. 356,250 Class B Performance SharesBulleen Pty Ltd1. 650,000 ordinary shares
Nature of changeExample: on-market trade, off-market trade, exerciseof options, issue of securities under dividendreinvestment plan, participation in buy-back	Conversion of 745,962 Class D PerformanceShares
Part 2 – Change of director’s interests in contractsNote: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” shouldbe disclosed in this part.
Detail of contract		N/A
Nature of interest		N/A
Name of registered holder(if issued securities)		N/A
Date of change		N/A
No. and class of securities to which interest related prior tochangeNote: Details are only required for a contract in relation to which the interest has changed		N/A
Interest acquired		N/A
Interest disposed		N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimated valuation		N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest after change	N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearance wasrequired?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3